Nobelpharma
As of the edition of 20 October 2026, Nobelpharma runs 24 drugs, 16 of them marketed; it is on route A at 0 targets and on route B at 11 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 2 company names in this family.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 16 |
| Went quiet | 3 |
| Stopped | 2 |
| Status not established | 3 |
| Total | 24 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Sirolimus | none listed | 1 |
| Sargramostim | Ended 2025 (orphan exclusivity) | 2 |
| Melatonin | none listed | 2 |
| Caffeine | none listed | 12 |
| Ethinyl estradiol | none listed | 5 |
| Carmustine | none listed | 1 |
| Levonorgestrel | none listed | 4 |
| Aminolevulinic acid | none listed | 0 |
| Oxcarbazepine | none listed | 10 |
| Norethindrone | none listed | 3 |
| Phenobarbital | Ends 2029 (exclusivity) | 0 |
| Zinc acetate anhydrous | none listed | 0 |
| Streptozocin | none listed | 0 |
| Fosphenytoin | none listed | 0 |
| Trafermin | none listed | 1 |
| Talc anhydrous | none listed | 0 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 0 targets, route B at 11 targets.
All 11 rows on route A or B
In the product11 company-target rows on route A or B; 8 are not shown here, and no score is.
See all 11 targets where Nobelpharma needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Cancer: 2 trials led
- Infections: 2 trials led
- Inherited and neonatal: 1 trials led